A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
NCT00036543 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2006-08-15
Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Darryl Sleep, M.D. · Abbott
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-05-31
Countries
- United States
- Australia
- Austria
- Belgium
- Canada
- France
- Germany
- Greece
- Ireland
- Italy
- Netherlands
- New Zealand
- Poland
- South Africa
- Spain
- Sweden
- Switzerland
- United Kingdom
Study Locations
More Related Trials
-
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT00887198 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
NCT00286793 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
NCT04262154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
NCT00134056 ·Status: COMPLETED ·Phase: PHASE3
-
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
NCT00003516 ·Status: TERMINATED ·Phase: PHASE2
-
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
NCT03436654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
NCT00571675 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005847 ·Status: COMPLETED ·Phase: PHASE2
-
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
NCT00003534 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
NCT00257478 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
NCT04056754 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01549951 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
NCT01685268 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
NCT04089553 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
NCT03879122 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
NCT00473512 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
NCT00183924 ·Status: COMPLETED ·Phase: PHASE2
-
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
NCT04887506 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT01715285 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
NCT00314782 ·Status: COMPLETED ·Phase: PHASE1
-
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer
NCT03458247 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Open Label Prostate Cancer Study
NCT01162395 ·Status: COMPLETED ·Phase: PHASE1